Media Releases

PhRMA Statement on India Supreme Court Decision on Glivec

WASHINGTON, D.C. (April 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today: “PhRMA is very disappointed with the Indian Supreme Court’s decision to deny a patent on Glivec. This decision marks yet another example of the deteriorating innovation environment in India. Innovation is critical in meeting unmet needs of patients and is particularly relevant in the context of changing healthcare systems. In order to solve the real health challenges of India’s patients, it is critically important that India promote a policy environment that supports continued research and development of new medicines for the health of patients in India and worldwide. Protecting intellectual...

Latest Releases

PhRMA Releases New Data on Biopharmaceutical Industry’s Contributions to Local, State Economies

11/14/2012

Results from 17 states represent nearly $53 billion spent with broad network of large, small businesses

Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released new data highlighting the biopharmaceutical industry’s vital role in contributing to the U.S. economy. The data represent approximately $53 billion across 17 states, spent with businesses that provide important services and supplies in support of the industry’s mission to bring new medicines to patients. The results provide data at the local level for a subset of biopharmaceutical companies, and offer an impression of the industry’s impact on communities across the country.

Innovation & Adherence: Two Paths to Better Controlling Diabetes

11/12/2012

Ipsen Biopharmaceuticals and Onyx Pharmaceuticals Join PhRMA as Research Associate Members

America’s biopharmaceutical research companies currently are developing 221 innovative new medicines to help the nearly 26 million patients in the United States affected by diabetes. These medicines in development – all in either clinical trials or under review by the Food and Drug Administration (FDA) – include 32 for type 1 diabetes, 130 for type 2 and 64 for diabetes-related conditions, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Rotary International and Global Partners Contribute to a Polio-Free India

11/3/2012

Washington, D.C. (November 3, 2012) — The Pharmaceutical Research and Manufacturers of America (PhRMA) and its members are pleased to celebrate one of the most significant global health achievements of the 21st century. For over the past three years, we have supported Rotary International’s PolioPlus program in India through grants and contributions, some of which have been matched by the Bill and Melinda Gates Foundation.

PhRMA Statement on Rx Response’s Pharmacy Status Reporting Tool Activation in 11 States and the District of Columbia

10/31/2012

Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today on Rx Response activation in the wake of Hurricane Sandy:

PDUFA V Sets New Course for Regulatory Science – Joint BIO/PhRMA Statement

10/1/2012

Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani and Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood today released the following joint statement on the implementation of the Prescription Drug User Fee Act (PDUFA V):

PhRMA Statement on Avalere Health Analysis on Medicare Part D Premiums

9/25/2012

Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today on findings from Avalere Health on Medicare Part D premiums:

Your name
Your email
Recipient email(s) (separated by commas)
Subject

Media Releases

Latest Releases

Subscribe to our Email Updates